Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
26 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
PharmaFluidics from Gent, company number BE0832350565, closed financial year 2025 with a result of € -1.6 million after tax. For that financial year PharmaFluidics recorded revenue of € 1.4 million and equity of € 15.9 million. Compared with financial year 2024, the result moved from € -1.9 million to € -1.6 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 8, 2026.
€ 15.9 million
▼ 9% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1.6 million
▲ 15 % less loss than in 2024
Profit after tax over the fiscal year.
€ 69,334
▼ 42% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -6 million.
People and assets in 2025
13.8
▼ 0.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.6 million
▲ 2% vs 2024
€ 113,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 33,902
▼ 36% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 118,147
▼ 48% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 287,057
▼ 25% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | - | - | € 1,438,123 | |
| Gross margin | € -1,916,780 | € 167,834 | € 89,004 | € 387,531 | ▲ € 298,528 |
| Profit after taxes | € -5,845,344 | € -2,540,955 | € -1,853,318 | € -1,584,416 | ▲ € 268,902 |
| Equity | € 1,856,805 | € 19,315,850 | € 17,462,533 | € 15,878,117 | ▼ 9% |
| Total debts | € 3,399,956 | € 1,033,053 | € 731,043 | € 474,619 | ▼ 35% |
| Cash | € 512,309 | € 159,282 | € 120,440 | € 69,334 | ▼ 42% |
| Land & buildings | € 73,180 | € 141,823 | € 142,384 | € 108,162 | ▼ 24% |
| Retained profit | € -11,151,668 | € -2,539,095 | € -4,392,413 | € -5,976,829 | ▼ € 1.6 million |
| Balance sheet total | € 5,256,762 | € 20,348,903 | € 18,193,575 | € 16,352,736 | ▼ 10% |
| Employees (FTE) | 14 | 13.4 | 14 | 13.8 | ▼ 0.2 |
Key figures of PharmaFluidics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PharmaFluidics?
What happened at PharmaFluidics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Paul JACOBS stepped down as director. NBB
- Petrus VAN DER ZANDE stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 1.6 million. Source: NBB ↗
- Paul JACOBS became a director. NBB
- Petrus VAN DER ZANDE became a director. NBB
- New establishment in Gent. KBO
- Start of the company according to the CBE. KBO
In short
From € 5.8 million loss in 2022 to € 1.6 million loss in 2025.
On average € 28,100 of value added per employee in 2025.
A new publication or filing at PharmaFluidics? We notify you, reason included.
Follow PharmaFluidicsDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of THERMO FISHER SCIENTIFIC comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PharmaFluidicsThe shares are held by THERMO FISHER SCIENTIFIC (100%).
Directors
According to the 2025 annual accounts
Paul JACOBS
Director
since 2025 · until 2031
Petrus VAN DER ZANDE
Director
since 2021 · until 2027
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Technologiepark-Zwijnaarde 82
9052 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 26 companies are registered at this address.
All companies at this address →CONTREL EUROPE
€ 250,724 gross margin · 2025
INCUBATIE- EN INNOVATIECENTRUM UNIVERSITEIT
€ 1.4 million gross margin · 2025
VP VENTURES
€ -1,670 gross margin · 2025
SENSNET
Inbiose
€ 6.3 million revenue · 2025
+21 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Canonical: https://www.thermofisher.com/uk/en/home/industrial/chromatography/chromatography-consumables/hplc-uhplc-columns/low-flow-hplc-columns.html
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
COMBELL-AS, BE
Domain
Domain
pharmafluidics.com
Registered
2010-12-13
Registrar
MarkMonitor Inc.
Expires
2026-12-13
Website info
Features
Security
Details
- Company number
- 0832.350.565
- VAT number
- BE 0832.350.565
- Registered office
- Technologiepark-Zwijnaarde 82, 9052 Gent
- Names & denominations
- PharmaFluidics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 29 December 2010
- Peppol
- Active · Active since 20 Nov 2020
- Contact
- pharmafluidics.com [email protected]
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van medische beeldvorming en medische laboratoria
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Activiteiten van medische laboratoria
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering